Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Outperform on Bruker, Raises Price Target to $100

SVB Leerink analyst Puneet Souda maintains Bruker (NASDAQ:BRKR) with a Outperform and raises the price target from $90 to $100.

byBenzinga Newsdesk

September 9, 2021

1 minute read

SVB Leerink analyst Puneet Souda maintains Bruker (NASDAQ:BRKR) with a Outperform and raises the price target from $90 to $100.

B of A Securities Upgrades Core Laboratories to Neutral

By Benzinga Newsdesk

Today, 6:02 AM

B of A Securities analyst Chase Mulvehill upgrades Core Laboratories (NYSE:CLB) from Underperform to Neutral.

CLB

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $3,200 Today

By Benzinga Insights

Today, 6:02 AM

TE Connectivity (NYSE:TEL) has outperformed the market over the past 15 years by 1.28% on an annualized basis producing an average annual return of 8.16%. Currently, TE Connectivity has a market capitalization of $41.75 billion.

TEL

Morgan Stanley Maintains Equal-Weight on 2U, Lowers Price Target to $28

By Benzinga Newsdesk

Today, 6:02 AM

Morgan Stanley analyst Josh Baer maintains 2U (NASDAQ:TWOU) with a Equal-Weight and lowers the price target from $37 to $28.

TWOU

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $12

By Benzinga Newsdesk

Today, 6:02 AM

HC Wainwright & Co. maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $9 to $12.

CPRX

SVB Leerink Maintains Outperform on Bruker, Raises Price Target to $100

Related Posts

B of A Securities Upgrades Core Laboratories to Neutral

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $3,200 Today

Morgan Stanley Maintains Equal-Weight on 2U, Lowers Price Target to $28

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $12